Maxim Group resumed coverage on AIM ImmunoTech with a new price target

2/9/21 4:10:39 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AIM

Date	Price Target	Rating	Analyst